Mohamad-Noor Abu-Hammour, MD1, Kamal Hassan, MD2, Rashid Abdel-Razeq, MD3, Barish Eren, MD4, Thabet Qapaja, MD3, Prabhat Kumar, MD4, Gianina Flocco, MD5, Islam B Mohamed, MD4, Aravinthan Vignarajah, MD4 1Cleveland Clinic Fairview, Cleveland, OH; 2New York-Presbyterian/Queens, New York, NY; 3Cleveland Clinic, Cleveland, OH; 4Cleveland Clinic Foundation, Cleveland, OH; 5Cleveland Clinic Foundation, Fairview Park, OH
Introduction: Statins are commonly used in patients with coronary artery disease (CAD), but their use in patients with concurrent cirrhosis raises concerns about potential hepatotoxic effects. This study aims to compare the impact of high-dose versus low-dose statin therapy on liver function tests (LFTs) in patients with CAD and cirrhosis.
Methods: A retrospective cohort study was conducted using the TriNetX platform, including patients diagnosed with CAD and cirrhosis who were treated with either high-dose (N=68,688) or low-dose statins (N=68,668). Propensity score matching was applied to balance baseline characteristics between the two cohorts. The primary outcome assessed was the incidence of abnormal LFTs.
Results: The incidence of abnormal LFTs was slightly lower in the high-dose group (9.13%) compared to the low-dose group (9.63%). The hazard ratio for abnormal LFTs in the high-dose group compared to the low-dose group was 0.942 (p< 0.001), indicating that high-dose statin therapy was not associated with an increased risk of abnormal LFTs.
Discussion: High-dose statin therapy in patients with CAD and cirrhosis is not associated with an increased risk of abnormal liver function tests compared to low-dose statin therapy. These findings support the safety of high-dose statin use in this patient population, alleviating concerns about potential hepatotoxicity.
Disclosures:
Mohamad-Noor Abu-Hammour indicated no relevant financial relationships.
Kamal Hassan indicated no relevant financial relationships.
Rashid Abdel-Razeq indicated no relevant financial relationships.
Barish Eren indicated no relevant financial relationships.
Thabet Qapaja indicated no relevant financial relationships.
Prabhat Kumar indicated no relevant financial relationships.
Gianina Flocco indicated no relevant financial relationships.
Islam B Mohamed indicated no relevant financial relationships.
Aravinthan Vignarajah indicated no relevant financial relationships.
Mohamad-Noor Abu-Hammour, MD1, Kamal Hassan, MD2, Rashid Abdel-Razeq, MD3, Barish Eren, MD4, Thabet Qapaja, MD3, Prabhat Kumar, MD4, Gianina Flocco, MD5, Islam B Mohamed, MD4, Aravinthan Vignarajah, MD4. P1252 - Low- vs High-Intensity Statin Therapy and it’s Association on Liver Function in Patients With Cirrhosis and Coronary Artery Disease, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.
